33results about How to "Meet the needs of clinical medicine" patented technology

The invention provides a positive ion lipid nanometer particle / DNA compound and a preparation technology thereof. The preparation technology comprises the following steps that (1) a positive ion lipidmaterial is dissolved in absolute ethyl alcohol through heating; (2) an ethyl alcohol solution prepared in the step (1) is added to an aqueous phase solution dropwise, and positive ion lipid nanometer particles are formed through self-assembling; (3) residue ethyl alcohol in the positive ion lipid nanometer particles of the step (2) is removed; (4) filtering is carried out; (5) a DNA solution isprepared; (6) the prepared positive ion lipid nanometer particles in the step (4) and the DNA solution prepared in the step (5) are mixed according to a certain weight ratio to form the positive ion lipid nanometer particle / DNA compound; and (7) filtering is carried out. According to the preparation technology of the positive ion lipid nanometer particle / DNA compound, the operation of the preparation method is easy and rapid, the particle diameter of the prepared positive ion lipid nanometer particle / DNA compound is 50-150 nm, PDI<0.3, the positive ion lipid nanometer particle / DNA compound isdistributed in a mono-dispersion mode, the structure is stable, the compound is subjected to filtering sterilization at a terminal, and the security of the compound in clinic application of preparation of tumor curing medicine is effectively ensured.

The invention relates to a new fungus that could produce taxales mellow-Alternaria alternate var.monosporus ST-026-R CGMCC No.0899. The invention also discloses the method to produce taxales mellow that includes the following steps: cultivating CGMCC 0899 in culture medium to produce and gather taxales mellow in the strain cell and the culture medium. Thus, the taxales mellow could be recycle and purify in the cell and culture medium. It could solve the technology problem of taxales mellow and protect natural resource.

The invention discloses a method for increasing the yield of paclitaxel in an endophytic fungus fermentation product. The method comprises the steps that an endophytic fungus seed solution for producing paclitaxel is inoculated into an endophytic fungus solid state fermentation medium containing taxus media and valeriana jatamansi for culture, the mixture is then put into an alternating magnetic field environment for further culture, and a endophytic fungus solid state fermentation product is obtained; then the endophytic fungus seed solution for producing paclitaxel is inoculated into a liquid fermentation medium containing the endophytic fungus solid state fermentation product for culture, and the final endophytic fungus fermentation product is obtained. According to the method, raw materials are natural, no pollution is caused to the environment, a cycle is short, the yield is high, the method is suitable for industrial production, and compared with a common endophytic fungus fermentation product, the yield of paclitaxel in the endophytic fungus fermentation product is obviously increased.

The invention relates to an injection using astragalus root glycosides extract as the active ingredient, which also comprises pharmaceutically acceptable adjunct for injection, the content of the astragalus root glycosides in the total astragalus root extract is 80-100%, each unit of the preparation contains astragalus root glycosides 90-300mg.

The invention discloses a compound composition of irbesartan and hydrochlorothiazide. The composition can be made into granules, capsules, tablets and coated tablets. By screening and adopting a specific adhesive, the dissolution rate of the active ingredient irbesartan can exceed 94%, and the dissolution rate of hydrochlorothiazide can exceed 96%; after the composition is placed for 10 days at a high temperature of 60 DEG C, the dissolution rates of the two active ingredients are basically kept unchanged; and therefore, the composition has good stability and can meet the needs of clinical medication.

The invention discloses an ibuprofen injection composite which can obviously improve the quality stability of products and meet the clinical compatibility demand and a preparation method thereof to overcome the defect of the traditional ibuprofen injection. The injection is prepared by mixing ibuprofen and cosolvent according to a molar ratio of 1: 1.001-2, and the pH value of the injection is 7.5-9.0. The ibuprofen injection prepared through the method has obviously improved tolerance capability to high temperature and strong light and better stability and no irritant to vessels, and can effectively meet the requirement of the clinical intravenous drip. Moreover, the preparation method of the invention has the advantages of simple process and good stability of the prepared product.

The invention provides a carbinoxamine maleate oral slow-release suspension which is prepared from impregnated carbinoxamine maleate-resin composite particles and a suspension matrix. The impregnatedcarbinoxamine maleate-resin composite particles are prepared by using an impregnating agent to impregnate a carbinoxamine-maleate-resin compound and performing wet-process granulation, and the impregnating agent comprises a slow-release material and a plasticizer. The invention further provides a preparation method of the suspension. The preparation method is simple; a novel administration systemtaking sodium polystyrene sulfonate as a carrier is adopted, medicine is combined with sodium polystyrene sulfonate, and the objectives of slow release and taste masking are achieved after impregnating through the impregnating agent and wet-process granulation.

The invention provides a cationic lipid nanoparticle / DNA complex and a preparation process thereof, the preparation process comprising the following steps: (1) dissolving the cationic lipid material in absolute ethanol by heating; (2) dissolving the step ( 1) The prepared ethanol solution is added dropwise to the aqueous phase solution to self-assemble to form cationic lipid nanoparticles; (3) remove the residual ethanol in step (2) cationic lipid nanoparticles; (4) filter. (5) prepare DNA solution; (6) mix the cationic lipid nanoparticle that step (4) prepares and the DNA solution that step (5) prepares according to certain mass ratio, to form cationic lipid nanoparticle / DNA complex ; (7) filter. The preparation method of the present invention is simple and quick to operate, and the prepared cationic lipid nanoparticle / DNA complex has a particle size of 50-150 nm, a PDI<0.3, a monodisperse distribution, and a stable structure, and the complex is sterilized by terminal filtration, The safety of the complex in the preparation of clinical application of tumor medicine is effectively guaranteed.

The invention relates to the technical field of medicine, in particular to hydrated icariin nanoparticles and a preparation method and application thereof. The hydrated icariin nanoparticles comprisehydrated icariin and a stabilizer. According to the hydrated icariin nanoparticles and the preparation method and application thereof, the stabilizer is adopted to enable water-insoluble hydrated icariin drugs to be uniformly dispersed in a water phase in the form of nano-sized particles, so that the problems of insolubility and difficult administration are solved, and the bioavailability of the hydrated icariin is improved; based on the hydrated icariin nanoparticles, the water-insoluble hydrated icariin drugs can be further prepared into various clinically common dosage forms through a modern preparation process so as to meet various clinical medication requirements; and meanwhile, the stabilizer can improve the biological activity of hydrated icariin and further improve the bioavailability of the hydrated icariin.

The invention relates to the field of pharmaceutical preparations, and in particular, relates to a polydatin pharmaceutical composition containing no organic solvent and a preparation method thereof.The polydatin pharmaceutical composition comprises polydatin, a solubilizing agent and a solvent. The solubilizing agent is polyethylene glycol dodecyl hydroxy stearate, and the solvent is water for injection or a pH buffer solution or a sodium chloride solution or a glucose solution. According to the polydatin pharmaceutical composition containing no organic solvent, the dosage form is a pharmaceutically acceptable conventional dosage form such as water for injection or pre-serviced water or an aqueous solution freeze-dried product prepared from normal saline. The preparation method of the polydatin pharmaceutical composition mainly comprises the steps of dissolution, filtration, sealed potting, sterilization, lamp examination and the like.

The invention provides a class of capsaicin-containing salicylate derivatives with general structural formula I and a preparation method thereof, and the derivatives have the uses of anti-inflammation, labor pain, anti-cancer, antibacterial and hypolipidemic.

The invention discloses methanesulfonic acid doxazosin controlling releasing tablets and a process for preparation, which contains a single-layer core, insoluble semi-permeable membrane, single drug-releasing eyelet on each side of the tablet, and depends on the osmotic pressure difference between inside and outside of the semi-permeable membrane medium. The invention realizes the control of linear releasing of methanesulfonic acid doxazosin by single-layer core structure, and can remain effective and steady blood and drug concentration. The curative effect is improved, the generation rate ofside effect is reduced, and the productive technology is greatly simplified.

The invention relates to the field of pharmaceutical preparations, and in particular, relates to a polydatin pharmaceutical composition containing no organic solvent and a preparation method thereof.The polydatin pharmaceutical composition comprises polydatin, a solubilizing agent and a solvent. The solubilizing agent is polyethylene glycol dodecyl hydroxy stearate, and the solvent is water for injection or a pH buffer solution or a sodium chloride solution or a glucose solution. According to the polydatin pharmaceutical composition containing no organic solvent, the dosage form is a pharmaceutically acceptable conventional dosage form such as water for injection or pre-serviced water or an aqueous solution freeze-dried product prepared from normal saline. The preparation method of the polydatin pharmaceutical composition mainly comprises the steps of dissolution, filtration, sealed potting, sterilization, lamp examination and the like.

The invention discloses a method for increasing the yield of paclitaxel in an endophytic fungus fermentation product. The method comprises the steps that an endophytic fungus seed solution for producing paclitaxel is inoculated into an endophytic fungus solid state fermentation medium containing taxus media and valeriana jatamansi for culture, the mixture is then put into an alternating magnetic field environment for further culture, and a endophytic fungus solid state fermentation product is obtained; then the endophytic fungus seed solution for producing paclitaxel is inoculated into a liquid fermentation medium containing the endophytic fungus solid state fermentation product for culture, and the final endophytic fungus fermentation product is obtained. According to the method, raw materials are natural, no pollution is caused to the environment, a cycle is short, the yield is high, the method is suitable for industrial production, and compared with a common endophytic fungus fermentation product, the yield of paclitaxel in the endophytic fungus fermentation product is obviously increased.

A dispersing tablet of Yixintong is prepared from the micropowdered Yixintong, lactose, microcrystalline cellulose, polyvinyl pyrrolidone, sodium laurylsulfate and carboxymethyl starch sodium through mixing, pulverizing, adding magnesium stearate and residual carboxymethyl starch sodium, stirring and die pressing.

The invention relates to a new fungus that could produce taxales mellow-Alternaria alternate var.monosporus ST-026-R CGMCC No.0899. The invention also discloses the method to produce taxales mellow that includes the following steps: cultivating CGMCC 0899 in culture medium to produce and gather taxales mellow in the strain cell and the culture medium. Thus, the taxales mellow could be recycle and purify in the cell and culture medium. It could solve the technology problem of taxales mellow and protect natural resource.

The invention discloses a composition containing polydatin and its application, which belongs to the technical field of polydatin application and aims to solve the technical problem of the limited solubility of polydatin in pure water or physiological saline solution. And this kind of polydatin-containing composition adopts composite hydrogel as loading agent, improves the solubility of polydatin in aqueous solution or saline solution, and makes it meet the needs of clinical medicine of polydatin; and the composite hydrogel utilizes Poloxamer has the property of reverse reversible thermal gelation, and the introduction of silk fibroin and carboxymethyl chitosan utilizes the carboxyl group on carboxymethyl chitosan to combine with the amino group on silk fibroin and poloxamer The hydroxyl group on the hydrogel reacts to form an interpenetrating network in the composite gel system, which improves the mechanical strength of the composite hydrogel, and there are hydrophilic segments of silk fibroin and poloxamer in the entire gel system, making the gel ‑Sol transition temperature tends to body temperature, suitable for human administration.

The invention discloses a compound triamcinolone acetonide acetate solution preparation method. According to the method, a solution product with excellent stability is obtained by adding appropriate amount of a sodium chloride aqueous solution; in addition, with adoption of the method, the production cost is low, the safety and effectiveness of the product are not affected, the environmental pollution pressure is not worsened, and industrial production and application are suitable.

The invention relates to an injection using astragalus root glycosides extract as the active ingredient, which also comprises pharmaceutically acceptable adjunct for injection, the content of the astragalus root glycosides in the total astragalus root extract is 80-100%, each unit of the preparation contains astragalus root glycosides 90-300mg.